

DAFTAR PUSTAKA

- Akbani, R., Akdemir, K. C., Aksoy, B. A., Albert, M., Ally, A., Amin, S. B *et al.* (2015). Genomic classification of cutaneous melanoma. *Cell*, 161(7), 1681-1696.
- Akslen, L.A., Angelini, S., Straume, O., Bachmann, I.M., Molven, A., et al, 2005. *BRAF and NRAS mutations are frequent in nodular melanoma but are not associated with tumor cell proliferation or patient survival*. Journal Investigative Dermatology 125, pp :312–317.
- ALBERTO, M., & FABRIZIOMARIA, G. (2021). The under-reporting of UV induced occupational non-melanoma skin cancers and actinic keratoses in Italy. In *Proceedings of the XXII World Congress on Safety and Health at Work*.
- Allais, B. S., Beatson, M., Wang, H., Shahbazi, S., Bijelic, L., Jang, S., & Venna, S. (2021). Five-year survival in patients with nodular and superficial spreading melanomas in the US population. *Journal of the American Academy of Dermatology*, 84(4), 1015-1022.
- Antohe, M., Nedelcu, R. I., Nichita, L., Popp, C. G., Cioplea, M., Brinzea, A *et al.* (2019). Tumor infiltrating lymphocytes: The regulator of melanoma evolution. *Oncology letters*, 17(5), 4155-4161.
- Barnhill, R.L., Piepkorn, M., Busam, K.J., (2014). *Pathology of Melanocytic Nevi and Melanoma*, 3rd ed. Springer-Verlag, Berlin Heidelberg.
- Blair, M. J., Jones, J. D., Woessner, A. E., & Quinn, K. P. (2020). Skin structure–function relationships and the wound healing response to intrinsic aging. *Advances in wound care*, 9(3), 127-143.
- Beleaua, M. A., Jung, I., Braicu, C., Milutin, D., & Gurzu, S. (2021). Relevance of BRAF Subcellular Localization and Its Interaction with KRAS and KIT Mutations in Skin Melanoma. *International Journal of Molecular Sciences*, 22(21), 11918.
- Bønnelykke-Behrndtz, M. L., & Steiniche, T. (2017). Ulcerated melanoma: aspects and prognostic impact. Cutaneous Melanoma: Etiology and Therapy [Internet].
- Cai, Y. J., Ke, L. F., Zhang, W. W., Lu, J. P., & Chen, Y. P. (2021). Recurrent KRAS, KIT and SF3B1 mutations in melanoma of the female genital tract. *BMC cancer*, 21(1), 1-9.
- Carr, S., Smith, C., & Wernberg, J. (2020). Epidemiology and risk factors of melanoma. *Surgical Clinics*, 100(1), 1-12.

- Cherobin, A. C. F. P., Wainstein, A. J. A., Colosimo, E. A., Goulart, E. M. A., & Bittencourt, F. V. (2018). Prognostic factors for metastasis in cutaneous melanoma. *Anais brasileiros de dermatologia*, 93, 19-26.
- Chida, K., Kotani, D., Masuishi, T., Kawakami, T., Kawamoto, Y., Kato, K *et al.* (2021). The prognostic impact of KRAS G12C mutation in patients with metastatic colorectal cancer: a multicenter retrospective observational study. *The oncologist*, 26(10), 845-853.
- Cicenas, J., Tamosaitis, L., Kvederaviciute, K., Tarvydas, R., Staniute, G., Kalyan, K *et al.* (2017). KRAS, NRAS and BRAF mutations in colorectal cancer and melanoma. *Medical Oncology*, 34(2), 1-11.
- Cosgarea, I., McConnell, A. T., Ewen, T., Tang, D., Hill, D. S., Anagnostou, M., & Lovat, P. E. (2022). Melanoma secretion of transforming growth factor- β 2 leads to loss of epidermal AMBRA1 threatening epidermal integrity and facilitating tumour ulceration. *British Journal of Dermatology*, 186(4), 694-704.
- D'Mello, S. A., Finlay, G. J., Baguley, B. C., & Askarian-Amiri, M. E. (2016). Signaling pathways in melanogenesis. *International journal of molecular sciences*, 17(7), 1144.
- Davies, J., Muralidhar, S., Randerson-Moor, J., Harland, M., O'Shea, S., Diaz, J., & Newton-Bishop, J. A. (2022). Ulcerated melanoma: Systems biology evidence of inflammatory imbalance towards pro-tumourigenicity. *Pigment Cell & Melanoma Research*, 35(2), 252-267.
- Degenhardt, K., Mathew, R., Beaudoin, B., Bray, K., Anderson, D., Chen, G., & White, E. (2006). Autophagy promotes tumor cell survival and restricts necrosis, inflammation, and tumorigenesis. *Cancer cell*, 10(1), 51-64.
- Dietrich, P., Kuphal, S., Spruss, T., Hellerbrand, C., & Bosserhoff, A. K. (2018). Wild-type KRAS is a novel therapeutic target for melanoma contributing to primary and acquired resistance to BRAF inhibition. *Oncogene*, 37(7), 897-911.
- Doeden, K., Ma, Z., Narasimhan, B., Swetter, S. M., Detmar, M., & Dadras, S. S. (2009). Lymphatic invasion in cutaneous melanoma is associated with sentinel lymph node metastasis. *Journal of cutaneous pathology*, 36(7), 772-780.
- Elder, D. E., Bastian, B. C., Cree, I. A., Massi, D., & Scolyer, R. A. (2020). The 2018 World Health Organization classification of cutaneous, mucosal, and uveal melanoma: detailed analysis of 9 distinct subtypes defined by their evolutionary pathway. *Archives of pathology & laboratory medicine*, 144(4), 500-522.

- Ellerhorst, J.A., Greene, V.R., Ekmekcioglu, S., Warneke, C.L., Johnson, M.M., et al., 2011. *Clinical correlates of NRAS and BRAF mutations in primary human melanoma*. *Human Cancer Biology* 17, pp : 229–235
- Ferreira, A., Pereira, F., Reis, C., Oliveira, M. J., Sousa, M. J., & Preto, A. (2022). Crucial Role of Oncogenic KRAS Mutations in Apoptosis and Autophagy Regulation: Therapeutic Implications. *Cells*, 11(14), 2183.
- Finn, S. P., Addeo, A., Dafni, U., Thunnissen, E., Bubendorf, L., Madsen, L. B & European Thoracic Oncology Platform Lungscape Investigators. (2021). Prognostic impact of KRAS G12C mutation in patients with NSCLC: results from the European Thoracic Oncology Platform Lungscape Project. *Journal of Thoracic Oncology*, 16(6), 990-1002.
- Guerrero, S., Figueras, A., Casanova, I., Farré, L., Lloveras, B., Capellà, G & Mangues, R. (2002). Codon 12 and codon 13 mutations at the K-ras gene induce different soft tissue sarcoma types in nude mice. *The FASEB Journal*, 16(12), 1642-1644.
- Hellmann, M. D., Friedman, C. F., & Wolchok, J. D. (2016). Combinatorial cancer immunotherapies. *Advances in immunology*, 130, 251-277.
- Hong, D. S., Fakih, M. G., Strickler, J. H., Desai, J., Durm, G. A., Shapiro, G. I., & Li, B. T. (2020). KRASG12C inhibition with sotorasib in advanced solid tumors. *New England Journal of Medicine*, 383(13), 1207-1217.
- Huang, F., Li, J., Wen, X., Zhu, B., Liu, W., Wang, J., & Zhang, X. (2022). Next-generation sequencing in advanced Chinese melanoma reveals therapeutic targets and prognostic biomarkers for immunotherapy. *Scientific Reports*, 12(1), 1-10.
- Ingkaninanda, P., Visessiri, Y., & Rutnin, S. (2015). Clinicopathological features and prognostic factors of malignant melanoma: a retrospective analysis of Thai patients in Ramathibodi hospital. *J Med Assoc Thai*, 98(8), 820-7.
- Jagtap SV, Khoja S, Billawaria S, Chou TSR, Jagtap SS. Acral Nodular Melanoma Presenting With Rapid Progression. *J Cutan Aesthet Surg*. 2021 Oct-Dec;14(4):426-432.
- Jang, S., Hong, M., Shin, M. K., Kim, B. C., Shin, H. S., Yu, E & Kim, J. W. (2017). KRAS and PIK3CA mutations in colorectal adenocarcinomas correlate with aggressive histological features and behavior. *Human pathology*, 65, 21-30.
- Jung, J. M., Won, C. H., Chang, S. E., Lee, M. W., Choi, J. H., & Lee, W. J. (2020). Lymphatic invasion in acral and non-acral melanoma: A comparative, clinicoprognostic study of primary cutaneous melanoma according to tumour site. *Pathology*, 52(6), 670-675.

- Kim, J. E., Chung, B. Y., Sim, C. Y., Park, A. Y., Lee, J. S., Whang, K. U & Lee, S. Y. (2019). Clinicopathologic features and prognostic factors of primary cutaneous melanoma: a multicenter study in Korea. *Journal of Korean medical science*, 34(16).
- Koulouridi, A., Karagianni, M., Messaritakis, I., Sfakianaki, M., Voutsina, A., Trypaki, M., ... & Souglakos, J. (2022). Prognostic value of kras mutations in colorectal cancer patients. *Cancers*, 14(14), 3320.
- Kozovska, Z., Gabrisova, V., & Kucerovala, L. (2016). Malignant melanoma: diagnosis, treatment and cancer stem cells. *Neoplasma*, 63(4), 510-517.
- Lambert, M. W., Maddukuri, S., Karanfilian, K. M., Elias, M. L & Lambert, W. C. (2019). The physiology of melanin deposition in health and disease. *Clinics in Dermatology*, 37(5), 402-417.
- Leonardi, G. C., Falzone, L., Salemi, R., Zanghi, A., Spandidos, D. A., Mccubrey, J. A., & Libra, M. (2018). Cutaneous melanoma: From pathogenesis to therapy. *International journal of oncology*, 52(4), 1071-1080.
- Liu, C., Zheng, S., Wang, Z., Wang, S., Wang, X., Yang, L & He, J. (2022). KRAS-G12D mutation drives immune suppression and the primary resistance of anti-PD-1/PD-L1 immunotherapy in non-small cell lung cancer. *Cancer Communications*.
- Lo, S. N., Scolyer, R. A., & Thompson, J. F. (2018). Long-term survival of patients with thin (T1) cutaneous melanomas: a Breslow thickness cut point of 0.8 mm separates higher-risk and lower-risk tumors. *Annals of surgical oncology*, 25(4), 894-902.
- Loh, C. Y., Chai, J. Y., Tang, T. F., Wong, W. F., Sethi, G., Shanmugam, M. K & Looi, C. Y. (2019). The E-cadherin and N-cadherin switch in epithelial-to-mesenchymal transition: signaling, therapeutic implications, and challenges. *Cells*, 8(10), 1118.
- Mihm Jr, M. C., & Mulé, J. J. (2015). Reflections on the histopathology of tumor-infiltrating lymphocytes in melanoma and the host immune response. *Cancer immunology research*, 3(8), 827-835.
- Milagre, C., Dhomen, N., Geyer, F. C., Hayward, R., Lambros, M., Reis-Filho, J. S., & Marais, R. (2010). A Mouse Model of Melanoma Driven by Oncogenic KRASKRAS Models of Melanoma. *Cancer research*, 70(13), 5549-5557.
- Monteiro, H. P., Rodrigues, E. G., Reis, A. K. A., Longo Jr, L. S., Ogata, F. T., Moretti, A. I & Stern, A. (2019). Nitric oxide and interactions with reactive oxygen species in the development of melanoma, breast, and colon cancer: A redox signaling perspective. *Nitric Oxide*, 89, 1-13.

- Muñoz-Couselo, E., Adelantado, E. Z., Ortiz, C., García, J. S., & Perez-Garcia, J. (2017). NRAS-mutant melanoma: current challenges and future prospect. *OncoTargets and therapy*, 10, 3941.
- Murtas, D., Maxia, C., Diana, A., Pilloni, L., Corda, C., Minerba, L & Perra, M. T. (2017). Role of epithelial–mesenchymal transition involved molecules in the progression of cutaneous melanoma. *Histochemistry and Cell Biology*, 148(6), 639-649.
- Pachmayr, E., Treese, C., & Stein, U. (2017). Underlying mechanisms for distant metastasis-molecular biology. *Visceral medicine*, 33(1), 11-20.
- Park, H. E., Yoo, S. Y., Cho, N. Y., Bae, J. M., Han, S. W., Lee, H. S & Kang, G. H. (2021). Tumor microenvironment-adjusted prognostic implications of the KRAS mutation subtype in patients with stage III colorectal cancer treated with adjuvant FOLFOX. *Scientific reports*, 11(1), 1-10.
- Piñero-Madrona, A., Ruiz-Merino, G., Cerezuela Fuentes, P., Martínez-Barba, E., Rodríguez-López, J. N., & Cabezas-Herrera, J. (2019). Mitotic rate as an important prognostic factor in cutaneous malignant melanoma. *Clinical and Translational Oncology*, 21(10), 1348-1356.
- Rabbie, R., Ferguson, P., Wong, K., Couturier, D. L., Moran, U., Turner, C & Adams, D. J. (2021). The mutational landscape of melanoma brain metastases presenting as the first visceral site of recurrence. *British journal of cancer*, 124(1), 156-160.
- Reggiani Bonetti, L., Barresi, V., Maiorana, A., Manfredini, S., Caprera, C., & Bettelli, S. (2018). Clinical impact and prognostic role of KRAS/BRAF/PIK3CA mutations in stage I colorectal cancer. *Disease markers*, 2018.
- Rinonce, H. T., Aji, R. P. M., Hayati, N. M., Pudjohartono, M. F., & Kameswari, B. (2019, December). Low BRAF V600 mutation prevalence in primary skin nodular melanoma in Indonesia: a real-time PCR detection among Javanese patients. In *BMC proceedings* (Vol. 13, No. 11, pp. 1-6). BioMed Central.
- Rinonce, H. T., Sastri, D. J., Trisnawati, F., Kameswari, B., & Ferronika, P. (2022). The frequency and clinicopathological significance of NRAS mutations in primary cutaneous nodular melanoma in Indonesia. *Cancer Reports*, 5(1), e1454.
- Saginala, K., Barsouk, A., Aluru, J. S., Rawla, P., & Barsouk, A. (2021). Epidemiology of melanoma. *Medical sciences*, 9(4), 63.
- Schlegel, N. C., von Planta, A., Widmer, D. S., Dummer, R., & Christofori, G. (2015). PI3K signalling is required for a TGF β -induced epithelial–

mesenchymal-like transition (EMT-like) in human melanoma cells. *Experimental dermatology*, 24(1), 22-28.

- Shain, A. H., & Bastian, B. C. (2016). From melanocytes to melanomas. *nature reviews Cancer*, 16(6), 345-358.
- Sheen, Y. S., Tan, K. T., Tse, K. P., Liao, Y. H., Lin, M. H., Chen, J. S & Chu, C. Y. (2020). Genetic alterations in primary melanoma in Taiwan. *British Journal of Dermatology*, 182(5), 1205-1213.
- Shen, H., & Wu, W. (2015). Study of melanin bleaching after immunohistochemistry of melanin-containing tissues. *Applied immunohistochemistry & molecular morphology*, 23(4), 303.
- Sideris, M., Moorhead, J., Diaz-Cano, S., Haji, A., & Papagrigroriadis, S. (2017). KRAS mutant status may be associated with distant recurrence in early-stage rectal cancer. *Anticancer Research*, 37(3), 1349-1357.
- Souza, B. D. C., Silva, D. H. M., Miyashiro, D., Kakizaki, P., & Valente, N. Y. S. (2020). Clinicopathological analysis of acral melanoma in a single center: a study of 45 cases. *Revista da Associação Médica Brasileira*, 66, 1391-1395.
- Stolze, B., Reinhart, S., Bullinger, L., Fröhling, S., & Scholl, C. (2015). Comparative analysis of KRAS codon 12, 13, 18, 61 and 117 mutations using human MCF10A isogenic cell lines. *Scientific reports*, 5(1), 1-9.
- Tas, F., & Erturk, K. (2017). Tumor infiltrating lymphocytes (TILs) may be only an independent predictor of nodal involvement but not for recurrence and survival in cutaneous melanoma patients. *Cancer Investigation*, 35(8), 501-505.
- Tas, F., & Erturk, K. (2021). Primary tumour ulceration in cutaneous melanoma: its role on TNM stages. *Japanese Journal of Clinical Oncology*, 51(2), 192-198.
- Timar, J., & Kashofer, K. (2020). Molecular epidemiology and diagnostics of KRAS mutations in human cancer. *Cancer and Metastasis Reviews*, 39(4), 1029-1038.
- Trinidad, C. M., Torres-Cabala, C. A., Curry, J. L., Prieto, V. G., & Aung, P. P. (2019). Update on eighth edition American Joint Committee on Cancer classification for cutaneous melanoma and overview of potential pitfalls in histological examination of staging parameters. *Journal of clinical pathology*, 72(4), 265-270.
- Tsai, K. C., Hung, S. J., Wang, J. H., Huang, S. J., Wang, C. H., Lee, J. T & Chang, C. H. (2019). Cutaneous malignant melanoma in Eastern Taiwan: Clinicopathologic analysis of 56 cases. *Dermatologica Sinica*, 37(4), 187.

- Vanni, I., Tanda, E. T., Dalmasso, B., Pastorino, L., Andreotti, V., Bruno, W & Ghiorzo, P. (2020). Non-BRAF mutant melanoma: molecular features and therapeutical implications. *Frontiers in Molecular Biosciences*, 7, 172.
- Väyrynen, S. A., Väyrynen, J. P., Klintrup, K., Mäkelä, J., Karttunen, T. J., Tuomisto, A., & Mäkinen, M. J. (2016). Clinical impact and network of determinants of tumour necrosis in colorectal cancer. *British journal of cancer*, 114(12), 1334-1342.
- Vivekanandhan, S., & Mukhopadhyay, D. (2019, February). Genetic status of KRAS influences Transforming Growth Factor-beta (TGF- β) signaling: An insight into Neuropilin-1 (NRP1) mediated tumorigenesis. *In Seminars in cancer biology* (Vol. 54, pp. 72-79). Academic Press.
- Wheless, L., Isom, C. A., Hooks, M. A., & Kauffmann, R. M. (2018). Mitotic rate is associated with positive lymph nodes in patients with thin melanomas. *Journal of the American Academy of Dermatology*, 78(5), 935-941.
- Wyatt, C., Lucas, R. M., Hurst, C., & Kimlin, M. G. (2015). Vitamin D deficiency at melanoma diagnosis is associated with higher Breslow thickness. *PLoS One*, 10(5), e0126394.
- Yun, J., Nakagawa, R., & Tham, K. (2022). KRAS-targeted therapy in the treatment of non-small cell lung cancer. *Journal of Oncology Pharmacy Practice*, 10781552221118848.